Alnylam Pharmaceuticals

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY

Retrieved on: 
Giovedì, Marzo 7, 2024

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY).

Key Points: 
  • NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY).
  • The investigation concerns whether Alnylam and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • On February 15, 2024, Alnylam issued a press release announcing its fourth quarter and full year 2023 financial results.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Retrieved on: 
Mercoledì, Febbraio 28, 2024

REDWOOD CITY, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the fourth quarter and fiscal year ended December 31, 2023, and provided a business update.

Key Points: 
  • Including enzyme sales related to PAXLOVID™, total revenues were $26.6 million in fourth quarter 2023 compared to $30.4 million in fourth quarter 2022.
  • Including enzyme sales related to PAXLOVID™, product revenues were $18.1 million in fourth quarter 2023 compared to $23.3 million in fourth quarter 2022.
  • Product gross margin, excluding enzyme sales related to PAXLOVID™, was 71% for fourth quarter 2023 compared to 44% in fourth quarter 2022.
  • Including enzyme sales related to PAXLOVID™, product gross margin for fourth quarter 2023 was 84% compared to 64% in fourth quarter 2022.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY

Retrieved on: 
Mercoledì, Febbraio 28, 2024

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY).

Key Points: 
  • NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY).
  • The investigation concerns whether Alnylam and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • On February 15, 2024, Alnylam issued a press release announcing its fourth quarter and full year 2023 financial results.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board

Retrieved on: 
Martedì, Febbraio 20, 2024

This board is now comprised of experts across oligonucleotide synthesis and manufacturing and was established to help guide the Company’s strategic direction, providing critical insights to inform the continued development of Codexis’ ECO Synthesis™ manufacturing platform.

Key Points: 
  • This board is now comprised of experts across oligonucleotide synthesis and manufacturing and was established to help guide the Company’s strategic direction, providing critical insights to inform the continued development of Codexis’ ECO Synthesis™ manufacturing platform.
  • “We are thrilled to have Masad and Jim lend their decades of experience in oligonucleotide research and development to our Strategic Advisory Board,” said Stefan Lutz, PhD, Senior Vice President of Research at Codexis.
  • Dr. Damha is a co-founder of Anagenis, Inc., a start-up with proprietary antisense technologies (ANA and FANA).
  • Presently, Dr. Lalonde serves as Chairman of the Board of Directors at Willow Biosciences and as a Scientific Advisory Board member at Bota Biosciences, bitBiome, Curie Co. and Invizyne.

Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives

Retrieved on: 
Martedì, Marzo 5, 2024

Zilebesiran demonstrated an encouraging safety and tolerability profile when added to these standard of care antihypertensives.

Key Points: 
  • Zilebesiran demonstrated an encouraging safety and tolerability profile when added to these standard of care antihypertensives.
  • “We are thrilled that a single dose of zilebesiran achieved clinically significant, additional reductions in systolic blood pressure when administered to patients who are not adequately controlled with commonly prescribed antihypertensives,” said Simon Fox, Ph.D., Vice President, Zilebesiran Program Lead at Alnylam.
  • “These KARDIA-2 results, showing durable additional levels of blood pressure reduction on top of what is achieved by standard of care first-line antihypertensives with an encouraging safety profile, reinforce our confidence in zilebesiran’s differentiated profile.
  • The primary endpoint is the change from baseline in mean SBP at Month 3, assessed by 24-hour ABPM.

Alnylam to Webcast Presentations at Upcoming March Investor Conferences

Retrieved on: 
Martedì, Febbraio 27, 2024

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:

Key Points: 
  • Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:
    TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 at 9:10 am ET in Boston
    Barclays 26th Annual Global Healthcare Conference on Tuesday, March 12, 2024 at 10:15 am ET in Miami
    Stifel 2024 CNS Day on Wednesday, March 20, 2024 at 10:00 am ET being held virtually
    Canaccord Genuity “Genetic Medicine for Generalists” on Monday, March 25, 2024 at 1:00 pm ET being held virtually
    A live audio webcast of each presentation will be available on the Investors section of the Company’s website at www.alnylam.com/events .
  • A replay will be available on the Alnylam website within 48 hours after each event.

ByHeart Appoints Amy Schulman as Chair of the Board of Directors, Further Solidifying its Position as a Leader in the Infant Nutrition Category

Retrieved on: 
Martedì, Marzo 5, 2024

NEW YORK, March 5, 2024 /PRNewswire/ --Today, ByHeart, the next-generation baby nutrition company, announced the appointment of Amy Schulman, managing partner at Polaris partners, as Chair of the Board. A stalwart supporter of ByHeart since its inception, Schulman's designation signifies a pivotal moment for the company as it experiences momentous growth and solidifies its position as an industry leader.

Key Points: 
  • "Amy's insights and passion for health innovation and social impact align with ByHeart's mission," said ByHeart Co-Founder and CEO Ron Belldegrun.
  • "We chose Amy as the Chair because of her extensive track record in life sciences and infant nutrition.
  • "I have been a staunch supporter of ByHeart from its early days, and I am honored to now chair their board," said Schulman.
  • ByHeart remains dedicated to advancing infant nutrition through science, innovation and a commitment to excellence.

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity

Retrieved on: 
Giovedì, Febbraio 15, 2024

GAAP R&D expenses further increased during the twelve month period due to increased stock-based compensation expense related to the accounting for certain performance-based awards during the period.

Key Points: 
  • GAAP R&D expenses further increased during the twelve month period due to increased stock-based compensation expense related to the accounting for certain performance-based awards during the period.
  • A reconciliation of our GAAP to non-GAAP results for the current quarter is included in the tables at the end of this press release.
  • The Company believes the presentation of non-GAAP financial measures provides useful information to management and investors regarding the Company’s financial condition and results of operations.
  • Non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures.

EQS-News: Investor interest returns – dividend yield remains high for 2024

Retrieved on: 
Mercoledì, Febbraio 14, 2024

Release as at February 14, 2024

Key Points: 
  • Release as at February 14, 2024
    After a difficult 2023 stock market year, above all due to higher interest rates, the capital markets are now once again looking at biotech companies with interest.
  • The prospect of falling interest rates has led to a rethink.
  • A dividend of this magnitude is exceptional not just in the Swiss equity market, but also in an international comparison.
  • Experts are anticipating similarly high approval figures for 2024 too.

Mary Beth DeLena Joins PepGen as General Counsel and Secretary

Retrieved on: 
Mercoledì, Gennaio 17, 2024

BOSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the expansion of its executive team with the appointment of Mary Beth DeLena as General Counsel and Secretary.

Key Points: 
  • BOSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the expansion of its executive team with the appointment of Mary Beth DeLena as General Counsel and Secretary.
  • Prior to PepGen, Mary Beth spent 15 years at Alnylam Pharmaceuticals in roles of increasing responsibility, most recently serving as Senior Vice President, Deputy General Counsel, and Assistant Secretary.
  • During her tenure at Alnylam, Mary Beth advised on multiple transformational strategic collaborations, licensing transactions, and significant capital-raising initiatives.
  • Mary Beth received her Juris Doctor from Northeastern University School of Law and her Bachelor of Arts in English from Trinity College.